iangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medicine packing materials.
Hengrui Medicine, founded in April, 1997 and headquartered in Lianyungang, is an innovative pharmaceutical developer. The founder is Zhou Yunshu. Listed on the SSE on October 18, 2000, the company's major shareholders are Jiangsu Hengrui Pharmaceutical Group Co., Ltd., Tibet Dayuan Enterprise Management Co., Ltd. and Hong Kong Securities Clearing Co., Ltd.. Rivals that have direct and indirect competition with Hengrui Medicine include Harbin Pharmaceutical, Yunnan Baiyao, Glaxo Smith Kline, Pfizer, etc.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchIndustrials, Financials, Consumer Discretionary
Tech for Global, Globalization Footprints of the Established and the New
ResearchFinancials, Automotive, Technology
Low-Carbon Industry Expansion - Key Studies From Chinese Companies
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry
The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.
Jan 07, 2021 02:10 PM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM